Catalyst Dossier · compiled by CeliA 🧫

Can-Fite BioPharma Ltd. (CANF)

Pharmaceutical Preparations · market cap $8M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2027-01-31

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2027-01-31Phase 3imp 6/10

Pipeline

Asset	Phase	Indication
CF 102	Phase 2	Chronic Hepatitis C
CF101 2mg	Phase 3	Plaque Psoriasis
Namodenoson 25mg	Phase 2	Pancreatic Adenocarcinoma
CF101	Phase 3	Rheumatoid Arthritis
Namodenoson	Phase 3	Hepatocellular Carcinoma
CF101 1mg	Phase 2	Plaque Psoriasis
Piclidenoson	Phase 2	COVID-19
CF102	Phase 2	Hepatocellular Carcinoma

Price & technical context

3-month

+13.7%

6-month

-20.9%

12-month

-82.9%

52-wk range

$2.75–$20.90

vs 50-day MA

+7.9%

vs 200-day MA

-35.3%

Realized vol

99.8%

Max drawdown

-96.9%

Daily closes through 2026-07-07. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for CANF (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.